FDA Grants Early Access to Breakthrough Pancreatic Cancer Drug
The US FDA approves expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.
The US FDA approves expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.